|
|
(103 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| ==Neutropenic Patients==
| | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center |
| * Patients with neutropenia require an antimicrobial therapy with a broader coverage.
| | |+ |
| * The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
| | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Tuberculin Rection}} |
| | | ! style="background: #4479BA; width: 450px;" | {{fontcolor|#FFF|Considered a Positive Result in:}} |
| {| style="border: 2px solid #696969;" | |
| |+ <SMALL>''Recommended Duration of Antimicrobial Therapy Based on the Microorganism.''</SMALL> | |
| | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''''Microorganism''''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Duration of Therapy'''
| |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Gram-negative Bacteria]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 7-14 days''''' | | | style="padding: 5px 5px; background: #DCDCDC;" | '''≥ 5 mm ''' |
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | *HIV-positive person |
| | *Recent contacts of TB case |
| | *Persons with nodular or fibrotic changes on CXR consistent with old healed TB |
| | *Patients with organ transplants and other immunosuppressed patients |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Gram-positive Bacteria]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 7-10 days''''' | | | style="padding: 5px 5px; background: #DCDCDC;" | '''≥ 10 mm ''' |
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | *Recent arrivals (less than 5 years) from high-prevalent countries |
| | *Injection drug users |
| | *Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.) |
| | *Mycobacteriology lab personnel |
| | *Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc) |
| | *Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Fungi]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' Until clinical resolution''''' | | | style="padding: 5px 5px; background: #DCDCDC;" | '''≥ 15 mm ''' |
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | *Persons with no known risk factors for TB |
| |- | | |- |
| |}
| |
|
| |
| <SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>
| |
|
| |
| {|
| |
| | valign=top |
| |
| <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;">
| |
| <font color="#FFF">
| |
| '''Neutropenia'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table25" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Gram-Negative Bacteria'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table26" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Gram-Positive Bacteria'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table27" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Fungi'''
| |
| </font>
| |
| </div>
| |
|
| |
|
| |
| | valign=top |
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table25" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Bacteria}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 0.5-1 g IV q8h (infuse over 15-30 min or in bolus over 3-5 min)'''''<br> OR <br> ▸ '''''[[Imipenem/cilastatin]] 0.5–1 g IV q6–8h(max: 50mg/kg/day)'''''<br> OR <br> ▸ '''''[[Ertapenem]] 1 g IV/IM q24h''''<br> OR <br> ▸ '''''[[Cefepime]] 2g IV q8h'''''<br> OR <br> ▸ '''''[[Ceftazidime]] 2g IV q8h'''''<br> OR <br> ▸ ''''' [[Piperacillin/tazobactam]] 3.375 g IV q6–8h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 1 '''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amikacin]] 15 mg/kg/day IV/IM divided q8-12h (max: 15 mg/kg/day)'''''<br> OR <br> ▸ '''''[[Gentamicin]] 3-5 mg/kg/day IV/IM divided q6-8h'''''<br> OR <br> ▸ '''''[[Gentamicin]] 4-7 mg/kg/day IV q24h <small>(adjust dosage based on serum concentrations)</small>'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Cefepime]] 2g IV q8h'''''<br> OR <br> ▸ ''''' [[Piperacillin/tazobactam]] 3.375 g IV q6–8h (max 24 g/day)'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 2 '''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ ''''' [[Piperacillin/tazobactam]] 3.375 g IV q6–8h (max 24 g/day)'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ ''''' [[Ciprofloxacin]] 400mg IV q8h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Positive Bacteria}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen '''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]]† 15-20 mg/kg IV q8-12h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4mg/kg IV q24h'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left | <small>† Vancomycin should be discontinued if culture results remain negative after 72-96 hrs </small>
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Fungi}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day IV × 1-2 weeks''''' <br> OR <br> ▸ '''''[[Amphotericin B]] deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks'''''<br> OR <br> ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day IV × 1-2 weeks'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Voriconazole]] 6 mg/kg IV q12h x 1 day, then 3 mg/kg IV q12h'''''<br> OR <br> ▸ '''''[[Voriconazole]] 200 mg PO q12h''''' <br> OR <br> ▸ '''''[[Caspofungin]] 70 mg IV once, then 50 mg IV q24h x ≥ 14 days'''''
| |
| |}
| |
| |}
| |
| |}
| |
|
| |
| ==Cellular Immune Deficient Patients==
| |
| * Patients with cellular immunodeficiency require a pathogen-specific antimicrobial therapy.
| |
| * The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
| |
|
| |
| {| style="border: 2px solid #696969;"
| |
| |+ <SMALL>''Recommended Duration of Antimicrobial Therapy Based on the Microorganism.''</SMALL>
| |
| | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''''Microorganism''''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Duration of Therapy'''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Nocardia|Nocardia spp]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 3-12 months'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Atypical mycobacteria]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 3-6 weeks'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Cryptococcus|Cryptococcus spp]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 8-12 weeks'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Histoplasma|Histoplasma spp]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''≥ 12 months'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Varicella-zoster virus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 7-10 days'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Herpes simplex virus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 7 days'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''[[Cytomegalovirus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ''''' 21 days'''''
| |
| |-
| |
| |}
| |
|
| |
|
| |
|
| |
| {|
| |
| | valign=top |
| |
| <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;">
| |
| <font color="#FFF">
| |
| '''Bacteria'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table28" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Nocardia spp'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table29" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Atypical mycobacteria'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;">
| |
| <font color="#FFF">
| |
| '''Fungi'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table30" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Cryptococcus spp'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table31" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Histoplasma spp'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;">
| |
| <font color="#FFF">
| |
| '''Viruses'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table32" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Varicella-zoster virus'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table33" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Herpes simplex virus'''
| |
| </font>
| |
| </div>
| |
|
| |
| <div class="mw-customtoggle-table34" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Cytomegalovirus'''
| |
| </font>
| |
| </div>
| |
|
| |
| | valign=top |
| |
| {|class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table28" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Nocardia spp}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[TMP-SMX]] x 3-12 months'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 1'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadiazine]] 2-4 g PO 1 dose'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | FOLLOWED BY
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadiazine]] 2-4 g/day PO q4-8h x 3-12 months'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 1'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]] 250-500 mg IV q6-8h x 3-12 months '''''
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table29" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Atypical mycobacteria†}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Clarithromycin]] 500 mg PO q12h'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Ethambutol]] 15 mg/kg PO q24h'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | WITH OR WITHOUT‡
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Rifabutin]] 300 mg PO q24h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Azithromycin]] 500 mg PO q24h'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Ethambutol]] 15 mg/kg PO q24h'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | WITH OR WITHOUT‡
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Rifabutin]] 300-450 mg PO q24h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center |<small>† Adapted from Am J Respir Crit Care Med Vol 175. pp 367–416, 2007<ref name="GriffithAksamit2007">{{cite journal|last1=Griffith|first1=David E.|last2=Aksamit|first2=Timothy|last3=Brown-Elliott|first3=Barbara A.|last4=Catanzaro|first4=Antonino|last5=Daley|first5=Charles|last6=Gordin|first6=Fred|last7=Holland|first7=Steven M.|last8=Horsburgh|first8=Robert|last9=Huitt|first9=Gwen|last10=Iademarco|first10=Michael F.|last11=Iseman|first11=Michael|last12=Olivier|first12=Kenneth|last13=Ruoss|first13=Stephen|last14=von Reyn|first14=C. Fordham|last15=Wallace|first15=Richard J.|last16=Winthrop|first16=Kevin|title=An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases|journal=American Journal of Respiratory and Critical Care Medicine|volume=175|issue=4|year=2007|pages=367–416|issn=1073-449X|doi=10.1164/rccm.200604-571ST}}</ref> <br> ‡ </small>
| |
|
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table30" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cryptococcus spp}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Moderate Severe to Severe Disease
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day IV × 1-2 weeks''''' <br> OR <br> ▸ '''''[[Amphotericin B]] deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks'''''<br> OR <br> ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day IV × 1-2 weeks'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h x ≥12 months'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Mild to Moderate Disease
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h x ≥12 months'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2007;45(7):807-25.''<ref name="Wheat-2007">{{Cite journal | last1 = Wheat | first1 = LJ. | last2 = Freifeld | first2 = AG. | last3 = Kleiman | first3 = MB. | last4 = Baddley | first4 = JW. | last5 = McKinsey | first5 = DS. | last6 = Loyd | first6 = JE. | last7 = Kauffman | first7 = CA. | title = Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 45 | issue = 7 | pages = 807-25 | month = Oct | year = 2007 | doi = 10.1086/521259 | PMID = 17806045 }}</ref></SMALL>
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table31" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Histoplasma spp}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Liposomal Amphotericin B]] 3 mg/kg/day x 1- 2 weeks''''' <br> OR <br>
| |
| ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day x 1- 2 weeks'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | FOLLOWED BY
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Itraconazole]] 200mg q8h x 3 days '''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | FOLLOWED BY
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Itraconazole]] 200mg q12h x 6-12 months'''''
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table32" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Varicella-zoster virus}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] 10-12 mg/kg IV (infusion over 1 hour) q8h x 7-10 days'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Famciclovir]] 500 mg PO x 7-10 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] 500 mg PO x 7-10 days'''''
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table33" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Herpes simplex virus}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]] 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Famciclovir]] 500 mg PO x 7 days''''' <br> OR <br> ▸ '''''[[Valacyclovir]] 500 mg PO x 7 days'''''
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table34" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cytomegalovirus}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ganciclovir]] 5 mg/kg IV q12h x 21 days'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Valganciclovir]] 900 mg PO q12h x 21 days'''''
| |
| |-
| |
| |}
| |
| |}
| |
| |} | | |} |